Use and cost of disease-modifying therapies by Sonya Slifka Study participants: has anything really changed since 2000 and 2009?

Autor: R. Philip Kinkel, Lisa I. Iezzoni, Helene T Machado, Jonathan Levin, Meredith B. Rosenthal, Sarah L. Minden

Publikováno v: Multiple sclerosis journal-experimental, translational and clinical, vol 5, iss 1
Multiple Sclerosis Journal-Experimental, Translational and Clinical

Background Disease-modifying therapies benefit individuals with relapsing forms of multiple sclerosis, but their utility remains unclear for those without relapses. Objective To determine disease-modifying therapy use and costs in 2009, compare use i

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d07be901cc2a3b0573eb8b6642c5231e
https://escholarship.org/uc/item/0rb9n1kf